Prominent Oral Proteins And Peptides Market Trend for 2025: Breakthrough Oral Insulin Technologies In Diabetes Care

What Are the Projected Growth and Market Size Trends for the Oral Proteins And Peptides Market?
The market size for oral proteins and peptides has witnessed rapid expansion in the past few years. It is projected to escalate from $1.27 billion in 2024 to $1.56 billion in 2025, with a compound annual growth rate (CAGR) of 22.7%. The expansion during this historical period can be credited to the increasing incidence of chronic ailments, augmented investments in biotechnology for creating oral protein-based therapies, a growing predilection amongst consumers for non-invasive treatment methods, an expanding biopharmaceutical sector, and an intensified focus on personalized medicine.

The market for oral proteins and peptides is predicted to witness a surge during the upcoming years, expanding to a size of $3.49 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 22.3%. The growth over the forecast period can be linked to an emphasis on patient-centered medicines, a growing elderly population, increased healthcare spending, a mounting demand for cancer diagnostics, and a heightening liking for oral medications. The forecast period will likely see trends such as the creation of innovative oral peptides with improved stability and effectiveness, the usage of artificial intelligence in discovering drugs for oral formulations, enhancements in medical treatments, progress in drug delivery technologies, and the innovation of oral insulin formulations.

What Is Driving the Growth Trajectory of the Oral Proteins And Peptides Market?
The rise of the biopharmaceutical industry is anticipated to fuel the expansion of the oral proteins and peptides market in the future. Comprising a specific sector of the wider pharmaceutical industry, the biopharmaceutical sector is centred around the development, production, and distribution of drugs sourced from biological origins. Factors contributing to the industry's growth include advancements in biotechnology, an increased demand for personalized medication, a rising prevalence of chronic diseases, and amplified investment in research and development. Oral proteins and peptides play a critical role in biopharmaceuticals by offering a potential avenue for non-invasive therapeutic delivery, which improves patient adherence to treatments and reduces dependency on injections. They also provide targeted treatment for specific diseases with enhanced stability and absorption in the digestive tract. As stated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based European trade association for the pharmaceutical industry, in June 2023, the production of biopharmaceuticals in Europe accounted for $384,200 million (€340,000 million) in 2022. This marked an approximate growth of 4.95% from $366,267 million (€323,950 million) in 2021. This expansion of the biopharmaceutical sector is the driving force propelling the growth of the oral proteins and peptides market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

Which Leading Companies Are Shaping the Growth of the Oral Proteins And Peptides Market?
Major companies operating in the oral proteins and peptides market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

What Are the Major Trends Shaping the Oral Proteins And Peptides Market?
Prominent entities in the sphere of oral proteins and peptides are strategically focusing on the evolution of inventive products like Oral Semaglutide, to uplift patient adherence and comfort. Oral semaglutide serves as a pivotal medication, making significant strides in the realm of oral proteins and peptides. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is usually given as an injection for treating type 2 diabetes and lately, obesity. For instance, Novo Nordisk India, an Indian healthcare firm, took a ground-breaking step in diabetes care by launching the world's first oral semaglutide in January 2022. Semaglutide, a GLP-1 receptor analogue (GLP-1 RA) was traditionally available only in an injectable format, but now it offers a simpler oral alternative for handling type 2 diabetes. This pivotal development not just revolutionizes diabetes treatment, but also paves the way for future novelties in oral insulin patterns, potentially resulting in more efficient and patient-amicable treatment options.

What Are the Key Segments of the Oral Proteins And Peptides Market?
The oral proteins and peptidesmarket covered in this report is segmented -

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide
2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Oxalate, Other Biological Targets
3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action
4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:
1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)
2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment
3) By Insulin: Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations
4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Region Dominates the Oral Proteins And Peptides Market?
North America was the largest region in the oral proteins and peptides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Oral Proteins And Peptides Global Market Report?

- Market Size Analysis: Analyze the Oral Proteins And Peptides Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Oral Proteins And Peptides Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Oral Proteins And Peptides Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Oral Proteins And Peptides Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19629

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.